Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial - PACE-CME

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

FCS and SHTG: Are We Meeting the Need?
FCS and SHTG: Are We Meeting the Need?
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
- Ira J. Goldberg, MD
- Kausik Ray, MBChB, MD, MPhil
- Christie Ballantyne
0.25 credits
Bempedoic acid reduces adverse limb events in patients with PAD
Bempedoic acid reduces adverse limb events in patients with PAD
AHA 2024
Bempedoic acid reduces adverse limb events in patients with PAD
- Marc Bonaca, MD
Promising results with oral Lp(a) inhibitor in phase 2 trial
Promising results with oral Lp(a) inhibitor in phase 2 trial
AHA 2024
Promising results with oral Lp(a) inhibitor in phase 2 trial
- Stephen Nicholls, FRACP, FACC, FESC, FAHA
Early and sustained non-HDL-c target achievement after MI
Early and sustained non-HDL-c target achievement after MI
Hyperlipidemia
Early and sustained non-HDL-c target achievement after MI
- Jessica Schubert, MD